FERRARO, SARA Statistiche

FERRARO, SARA  

DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE  

Mostra records
Risultati 1 - 20 di 30 (tempo di esecuzione: 0.029 secondi).
Titolo Data di pubblicazione Autore(i) File
A Model-Based Analysis on Direct Costs of Adverse Drug Events and Related Cost-Savings Achievable by their Prevention in Tuscany, Italy 1-gen-2018 Convertino, I; Salvadori, S; Pecori, A; Galiulo, Mt; Ferraro, S; Parrilli, M; Corona, T; Turchetti, G; Blandizzi, C; Tuccori, M
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) 1-gen-2021 Bartolini, C; Ferraro, S; Convertino, I; Bertani, L; Giometto, S; Costa, F; Blandizzi, C; Lucenteforte, E; Gini, R; Tuccori, M
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future 1-gen-2021 Tuccori, M.; Convertino, I.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Fini, E.; Focosi, D.
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study) 1-gen-2021 Pagani, S.; Lombardi, N.; Crescioli, G.; Vighi, G. V.; Spada, G.; Romoli, I.; Andreetta, P.; Capuano, A.; Marrazzo, E.; Marra, A.; Leoni, O.; Vannacci, A.; Venegoni, M.; Vighi, G. D.; Bettoni, D.; Blandizzi, C.; Bonaiuti, R.; Borsi, V.; Cecchi, E.; Convertino, I.; Del Lungo, M.; Di Mauro, C.; Farina, G.; Ferraro, S.; Fucile, A.; Galfrascoli, E.; Geninatti, E.; Giovannetti, L.; Leonardi, L.; Liccardo, R.; Monina, G.; Mugelli, A.; Pagani, S.; Parrilli, M.; Rafaniello, C.; Rossi, F.; Rostan, S.; Ruocco, M.; Sironi, M.; Sportiello, L.; Tuccori, M.
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline 1-gen-2020 Tuccori, M.; Ferraro, S.; Convertino, I.; Cappello, E.; Valdiserra, G.; Blandizzi, C.; Maggi, F.; Focosi, D.
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease 1-gen-2019 Blandizzi, C; Tuccori, M; Ferraro, S; Leonardi, L; Convertino, I
Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports 1-gen-2019 Ferraro, S; Leonardi, L; Blandizzi, C; Convertino, I; Tuccori, M
Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study 1-gen-2019 Convertino, I; Leonardi, L; Tuccori, M; Ferraro, S; Salvadori, S; Franchini, M; De Carlo, I; Kirchmayer, U; Corona, T; Riengler, S; Menditto, E; Parrilli, M; Rossi, M; Orlando, V; Pieroni, S; Vannacci, A
Anticoagulant Therapy in Patients with Atrial Fibrillation and Risk of Bleeding: Interim Analysis: Tyrion Study 1-gen-2018 Ferraro, S; Convertino, I; Salvadori, S; Pieroni, S; Pecori, A; Franchini, M; De Carlo, I; Kirchmayer, U; Corona, T; Parrilli, M; Rossi, M; Vannacci, A; Blandizzi, C; Tuccori, M
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy 1-gen-2021 Ferraro, S; Bartolini, C; Convertino, I; Bertani, L; Giometto, S; Cappello, E; Valdiserra, G; Tillati, S; Blandizzi, C; Lucenteforte, E; Costa, F; Gini, R; Tuccori, M
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study 1-gen-2021 Lorenzoni, V; Tuccori, M; Gini, R; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E; Turchetti, G
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients 1-gen-2020 Convertino, I.; Tuccori, M.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Focosi, D.; Blandizzi, C.
Listening Social Media for Pharmacovigilance Objectives: Which Usefulness? 1-gen-2019 Convertino, I; Leonardi, L; Tuccori, M; Ferraro, S; Blandizzi, C
Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy 1-gen-2021 Giometto, S; Convertino, I; Tuccori, M; Gini, R; Cazzato, M; Valdiserra, G; Cappello, E; Ferraro, S; Tillati, S; Fornili, M; Bartolini, C; Paoletti, O; Turchetti, G; Trieste, L; Lorenzoni, V; Blandizzi, C; Mosca, M; Lucenteforte, E
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs 1-gen-2021 Ferraro, S.; Tuccori, M.; Convertino, I.; Valdiserra, G.; Cappello, E.; Maggi, F.; Blandizzi, C.; Focosi, D.
Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact 1-gen-2019 Convertino, I; Lucenteforte, E; Lorenzoni, V; Turchetti, G; Trieste, L; Roberto, G; Cazzato, M; Mosca, M; Ferraro, S; Leonardi, L; Luciano, N; Gini, R; Blandizzi, C; Tuccori, M
Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data 1-gen-2021 Cucchiara, F.; Ferraro, S.; Luci, G.; Bocci, G.
Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments 1-gen-2020 Lombardi, N.; Bettiol, A.; Crescioli, G.; Ravaldi, C.; Bonaiuti, R.; Venegoni, M.; Vighi, G. D.; Mugelli, A.; Mannaioni, G.; Vannacci, A.; Aiezza, M. L.; Bettoni, D.; Blandizzi, C.; Borsi, V.; Capuano, A.; Cecchi, E.; Convertino, I.; Lungo, M. D.; Mauro, C. D.; Farina, G.; Ferraro, S.; Fucile, A.; Galfrascoli, E.; Geninatti, E.; Giovannetti, L.; Leonardi, L.; Liccardo, R.; Marra, A.; Marrazzo, E.; Monina, G.; Pagani, S.; Parrilli, M.; Rafaniello, C.; Rossi, F.; Rossi, M.; Rostan, S.; Ruocco, M.; Sironi, M.; Spada, G.; Sportiello, L.; Tuccori, M.; Vighi, G. V.
Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy 1-gen-2019 Convertino, I; Tuccori, M; Lucenteforte, E; Mosca, M; Turchetti, G; Lorenzoni, V; Trieste, L; Ferraro, S; Leonardi, L; Roberto, G; Luciano, N; Blandizzi, C; Gini, R
The Anti-TNF Drugs and the Risk of Lymphoma, Skin Cancer and Melanoma: A Signal Detection Analysis 1-gen-2019 Leonardi, L; Fornili, M; Convertino, I; Lucenteforte, E; Del Lungo, M; Ferraro, S; Blandizzi, C; Giovannetti, L; Baglietto, L; Parrilli, M; Borsi, V; Di Giorgio, D